Markets
Complex Simplicity
Getty Images

OpenAI doesn’t have the cash to pay Oracle $300 billion — raising it will test the very limits of private markets

The ChatGPT maker plans to burn though $115 billion by 2029. No company in history has ever lit that much money on fire intentionally, let alone tried funding such a splurge through private markets alone.

There’s a playbook in Silicon Valley: raise some money; build something people want; raise a lot more money; burn it in the pursuit of growth. The core of this strategy is to swap money for time by acquiring talent, companies, infrastructure, and technologies, all in the pursuit of leapfrogging your competition in the burgeoning field you’re disrupting.

Then, if you’re successful in ascending to the top: kick back, up your prices, and rake in the billions.

From Uber to Amazon, Tesla to Facebook, this game plan has worked time and time again. Jokes on late-night talk shows about companies losing money year after year, or paying a billion dollars for then boutique apps like Instagram, have become unfunny fast, as Big Tech has swallowed advertising, apparel, and everything in between.

But no company has ever burned as much money as OpenAI is planning to.

In the last few weeks, major deals with Broadcom and Oracle have thrown into sharp relief just how insane OpenAI’s ambitions are. The Oracle deal alone is worth $300 billion over five years starting in 2027. OpenAI does not have that kind of cash.

In fact, four of the tech world’s big “cash incinerators” — Uber, Tesla, Snap, and Netflix — together burned a pathetic ~$42 billion during their respective heavily cash-burning periods.

Lossmaking big tech burning cash
Sherwood News

Per The Information, OpenAI is planning on burning $115 billion through 2029. Given that the company raised “only” $40 billion earlier this year — and $64 billion in its lifetime to date, per Pitchbook data — it’s fair to assume that OpenAI will have to dip into the capital markets again to raise another $50 billion to $75 billion to fund its spending splurge.

And OpenAIs funding needs might not stop there — after that monstrous 2029 spending figure is reached, the company could still be on the hook for hundreds of billions of dollars as part of the freshly inked deal with Oracle, which runs for five years and only starts in 2027.

We’re going to need a bigger cap table

Just a few years ago, the idea of raising that amount on the deeply liquid public markets would have been remarkable; the biggest IPO ever was 2014’s Alibaba, which raised $25 billion — a figure that might not cover even a single year of OpenAI’s peak cash burn. Doing it in private markets would have been near unthinkable. Doing it as a complicated entity controlled by a “not-for-profit” entity? Insane.

Last week, the company revealed it had made progress on that last point. The Financial Times reported that OpenAI and Microsoft had signed a “non-binding memorandum of understanding” marking “a significant step forward in the start-up’s effort to convert to a more investor-friendly, for-profit structure.” That could unlock a potential IPO, giving institutional and retail investors the ability to invest directly in the company.

But in August, CEO Sam Altman said that an IPO was not a priority, suggesting there’s a very good chance that OpenAI continues to fund its runway via the private scene.

If the company pulls it off — raises all that money and finds a way to make the unit economics of its chatbot work along the way — it will raise a major question: is the stock market doing its primary job? If the most capital-hungry business of all time doesn’t need to raise on the public markets, we may need to rethink our textbook definitions of the stock market. The capital-allocating conduit that’s been the bedrock of American capitalism for more than a century is increasingly about price discovery, liquidity, and risk transfer, and less about capital formation.

What’s most remarkable, though, is that this might be quite an easy feat for OpenAI. Given the pervasive AI mania that we find ourselves experiencing in 2025, it’s hard to imagine that the world’s leading consumer-facing AI company will struggle to find investors for its cap table in the private markets, even at a nosebleed valuation of $500 billion and even with evidence that AI adoption might be cooling.

Related reading: Where did all the stocks go?

More Markets

See all Markets
markets

Space stocks rip amid speculation on Altman joining race

Space stocks AST SpaceMobile, Planet Labs, and Rocket Lab all soared Thursday amid a recovery in the high-beta momentum class of shares coveted by some retail traders.

(High-beta momo stocks are basically shares that have been on a winning streak for a while, and tend to go up a lot more than the overall market on positive days. Goldman Sachs includes all three of the aforementioned space stocks in its themed basket of such shares.)

There’s little other fundamental news out there on the companies themselves.

But a Wall Street Journal report that OpenAI impresario Sam Altman has been toying with the idea of entering the space industry, potentially standing up a rival to Tesla CEO Elon Musk’s Starlink satellite service, may also be contributing.

As we’ve mentioned elsewhere, sometimes these stocks seem to trade on a what’s-bad-for-the-Musk-empire-is-good-for-us-and-vice-versa vibe.

markets

Intel sinks on news it will hang on to networking unit

Intel dropped in early trading Thursday after it disclosed plans to retain ownership of its networking unit following a strategic review of operations.

The unit, known as NEX, makes products like infrastructure processors, which do needed “housekeeping” tasks like running security checks, thereby freeing core Intel CPUs to do the higher-value operations. It also produces switches and controllers that manage and direct the flow of data to CPUs.

markets

Quantum computing stocks soar on return of bullish options bets

The calendar says December, but the price action is starting to look a lot more like September to me:

Quantum computing companies IonQ, Rigetti Computing, and D-Wave Quantum are all up at least 7% as of 11:04 a.m. ET, buoyed by a wave of bullish options activity.

  • Nearly 50,000 calls in IonQ have already changed hands, well above the 20-day average for a full session, with activity concentrated in strikes from $50 to $55 in contracts that expire between Friday and mid-January. Its put/call ratio is near 0.2, versus an average of over 1 for the past 20 sessions.

  • More than 65,000 calls have traded in Rigetti, a hair shy of its full 20-day average. Like IonQ, options activity has a bullish tilt, with a put/call ratio of about 0.7 versus a 20-day average of roughly 1.2.

  • D-Wave, which received positive commentary from Evercore ISI on Wednesday, isn’t seeing call activity as elevated as its peers, but the options action is also very skewed toward the bull side, with a put/call ratio of less than 0.3 versus a 20-session average of 0.7.

Pure-play quantum computing stocks nearly doubled from late August to late September amid heavy options market activity thanks to reports on government support for the sector, M&A activity, tech breakthroughs, and a flurry of price target hikes by Wall Street.

markets

Hims announces acquisition of Canadian telehealth firm Livewell

Hims & Hers rose in early trading after it announced its acquisition of Livewell, a Canadian telehealth company, marking its official entrance to that market.

The company announced in July that it would expand into Canada by 2026, taking advantage of the patent expiry for semaglutide, the active ingredient in Novo Nordisk’s blockbuster GLP-1s, Ozempic and Wegovy. Hims said Thursday that it would do that through an all-cash acquisition of Livewell.

Novo’s patent on semaglutide is set to expire in Canada in January. It would be the first time generics for the blockbuster GLP-1 drugs are available anywhere, and generic drugmaker Sandoz International has already announced plans to make copies of the drug. In the US, Hims sells copycat versions of Novo’s drugs, which has led to conflict between the companies.

On Wednesday, Hims announced that it would purchase YourBio, a device that uses “bladeless microneedles thinner than an eyelash” to collect blood samples, in another all-cash deal. According to its latest quarterly filing, the company had $345.8 million in cash and cash equivalents.

Latest Stories

Sherwood Media, LLC produces fresh and unique perspectives on topical financial news and is a fully owned subsidiary of Robinhood Markets, Inc., and any views expressed here do not necessarily reflect the views of any other Robinhood affiliate, including Robinhood Markets, Inc., Robinhood Financial LLC, Robinhood Securities, LLC, Robinhood Crypto, LLC, or Robinhood Money, LLC.